GSK 2696277

Drug Profile

GSK 2696277

Alternative Names: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fondazione Telethon; GlaxoSmithKline; Ospedale San Raffaele
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Beta-thalassaemia

Most Recent Events

  • 09 Dec 2017 Efficacy data from the phase I/II TIGET-BTHAL trial in Beta-thalassaemia presented at the 59th American Society of Hematology Annual Meeting (ASH-2017)
  • 04 Oct 2017 Phase-II clinical trials in Beta-thalassaemia (In children, In adolescents, In adults, In the elderly) in Italy (Intraosseous) (NCT03275051)
  • 12 Sep 2017 GlaxoSmithKline plans a phase II trial for Beta-thalassaemia (In children, In adults, In adolescents, In elderly) (Intraosseous) (NCT03275051)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top